期刊文献+

瘤性体液中肿瘤血管生长因子的提取和检测 被引量:1

Entracing and detecting of tumor angiogenesis factor in cancerous tumor
下载PDF
导出
摘要 目的:建立科学有效的提纯、检测肿瘤血管生成因子(tumorangiogenesisfactor,TAF)的方法。方法:应用中空纤维超滤、超速离心、层析和电泳等方法,对肺癌及卵巢癌患者的胸腔积液、腹水中TAF进行提纯和分析;建立动物模型,采用鸡胚绒毛尿囊膜法检测其生物活性。结果:肺癌及卵巢癌患者的胸腔积液和腹水活性检测结果显示,87例中96.55%呈阳性,3.45%为阴性,差异有统计学意义。纯化的TAF经电泳后谱带清晰,相对分子质量为(4.6~4.8)×103,且具有生物活性,经免疫试验,抗体效价可达16.50。结论:所建立的提取、纯化及生物活性检测的方法稳定、有效,可用于观测抗肿瘤血管生成药物的药效或生物疗法的效果。肿瘤防治杂志,2005,12(17) OBJECTIVE: To established a scientifically effective method for extracting and detecting the tumor angiogenesis factor (TAF) in cancerous tumor. METHODS: TAF was purified at scheduled intervals by using extract methods such as hollow fiber column, ultracentrifugation, chromatography and electrophoresis. A creaturely model was established that was used to monitor the biological activity by the method of chicken embryo villus allantoid. RESULTS: Tissue samples were obtained from splanchnocoeles of 87 sufferers with carcinoma of lung, carcinoma of ovary and the data were treated by statistics. For quantitative data, the biological activity of samples was measured or calculated at scheduled intervals. As a result, the level of biological activity increased significantly by 96. 55% positive and 4.45% negative. As been shown in gel electrophoresis after purification, the band of TAF was sharp and the molecular weight (4.6-4.8) × 10^3 was identified. Furthermore. positively biological activity was detected. Antihody titer was 16.50. CONCLUSIONS: The method of extracting and detecting TAF in cancerous humor is stable and effective.
出处 《肿瘤防治杂志》 2005年第17期1289-1291,共3页 China Journal of Cancer Prevention and Treatment
基金 辽宁省科委立项课题(00225003)
关键词 肿瘤/诊断 体液/化学 血管生成因子 疾病模型 动物 neoplasms/diagnosis body fluids/chemistry angiogenesis factor disease models, animal
  • 相关文献

参考文献9

二级参考文献33

  • 1Jiang L,Jha V,Dhanabal M,et al.Intracellular Ca2+ signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin.Am J Physiol Cell Physiol.2001,280(5): 1140-1150.
  • 2Maeshima Y,Sudhakar A,Lively JC,et al.Tumstatin,an Endothelial Cell-specific Inhibitor of Protein Synthesis.Science,2002,295:140-143.
  • 3Bello L,Zhang J,Nikas J,et al.Alpha (v)beta3 and alpha(v)beta5 integrin expression in meningiomas.Neurosurgery,2000,47(5): 1185-1195.
  • 4Davidoff AM,Nathwani AC,Spurbeck WW.rAAV-mediated Long-term Liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice.Cancer Res,2002,62(11): 3077 - 3083.
  • 5Liekens S,De-Clercq E,Neyts J.Angiogenesis: regulators and clinical applications.Biochem Pharmacol,2001,61(3): 253-270.
  • 6Bergers G,Benjamin LE.Tumorigenesis and the angiogenic switch.Nat Rev Cancer,2003,3(6): 401-410.
  • 7Sanderson RD.Heparan sulfate proteoglycans in vasion and metastasis.Semin Cell Dev Biol,2001,12(2):89-98.
  • 8McMahon GA,Petitclere E,Stefansson S,et al.Plasminogen activation inhibitor-1 regulates tumor growth and angiogenesis.J Biol Chem,2001,276(36): 33964-33968
  • 9Cronauer MV,Schulz WA,Seifert HH,et al.Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications.Eur Urol.2003,43(3):309-319.
  • 10Breier G,Blum S,Peli J,et al.Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis.Int J Cancer,2002,97(2):142-148.

共引文献50

同被引文献10

  • 1Lamparski H G,Metha-Damani A,Yao J Y,et al.Production and characterization of clinical grade exosomes derived from dendritic cells[J].J Immunol Methods,2002,270(2):211-226.
  • 2Johnstone R M,Adam M,Hammond J R,et al.Vesicle formation during reticulocyte maturation.Association of plasma membrane activities with released vesicles (exosomes)[J].J Biol Chem,1987,262(19):9412-9420.
  • 3Altieri S L,Khan A N,Tomasi T B.Exosomes from plasmacytoma cells as a tumor vaccine[J].J Immunother,2004,27(4):282-288.
  • 4Bard M P,Hegmans J P,Hemmes A,et al.Proteomic analysis of exosomess isolated from human malignant pleural effusion[J].Am J Respir Cell Mol Biol,2004,31(1):114-121.
  • 5Chaput N,Taieb J,Schartz N E,et al.Exosome-based immunotherapy[J].Cancer Immunol Immunother,2004,53 (3):234-239.
  • 6Janowska-Wieczorek A,Wysoczynski M,Kijowski J,et al.Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer[J].Int J Cancer,2005,113(5):752-760.
  • 7de Gassart A,Geminard C,Hoekstra D,et al.Exosome secretion:the art of reutilizing nonrecycled proteins?[J].Traffic,2004,5(11):896-903.
  • 8Stahl P D,Barbieri M A.Multivesicular bodies and multivesicu lar endosomes:the "ins and outs' of endosomal traffic[J].Sci STKE,2002,141:32.
  • 9Andre F,Schartz N E,Movassagh M,et al.Malignant effu sions and immunogenic tumor-derived exosomes[J].Lancet,2002,360(9329):295-305.
  • 10罗治彬,徐采朴,王东,王阁,肖世全,朱高友,房殿春.致敏树突细胞及其亚细胞成分对荷胃癌小鼠的免疫治疗作用研究[J].世界华人消化杂志,2004,12(1):9-12. 被引量:8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部